GenomeWeb September 7, 2021
NEW YORK – Invitae announced Tuesday morning that it will acquire consumer health technology company Ciitizen for $325 million in a bid to make it easier for patients to collect their genomic and clinical information.
Ciitizen, which is backed by several investors, including a16z, Section 32, and Verily, is building a digital platform that will enable patients to collect, store, and share their medical records. Invitae has been expanding the genomic content of its testing platform and investing in software and data science capabilities to analyze patient data, and said that Ciitizen can help it create a centralized hub for medical data that can inform research and improve medical decision-making.
“We believe combining Ciitizen’s state-of-the-art, transparent, and patient-consented platform with...
Today's Sponsors
Today's Sponsor